Format

Send to

Choose Destination
Eur J Pharmacol. 2014 Jun 5;732:105-10. doi: 10.1016/j.ejphar.2014.03.023. Epub 2014 Mar 28.

Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Author information

1
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
2
Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
3
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA; School of Dentistry, University of Utah, Salt Lake City, Utah, USA.
4
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Electronic address: fleckenstein@hsc.utah.edu.

Abstract

Methamphetamine administration causes long-term deficits to dopaminergic systems that, in humans, are thought to be associated with motor slowing and memory impairment. Methamphetamine interacts with the dopamine transporter (DAT) and increases extracellular concentrations of dopamine that, in turn, binds to a number of dopamine receptor subtypes. Although the relative contribution of each receptor subtype to the effects of methamphetamine is not fully known, non-selective dopamine D2/D3 receptor antagonists can attenuate methamphetamine-induced changes to dopamine systems. The present study extended these findings by testing the role of the dopamine D3 receptor subtype in mediating the long-term dopaminergic, and for comparison serotonergic, deficits caused by methamphetamine. Results indicate that the dopamine D3 receptor selective antagonist, PG01037, attenuated methamphetamine-induced decreases in striatal DAT, but not hippocampal serotonin (5HT) transporter (SERT), function, as assessed 7 days after treatment. However, PG01037 also attenuated methamphetamine-induced hyperthermia. When methamphetamine-induced hyperthermia was maintained by treating rats in a warm ambient environment, PG01037 failed to attenuate the effects of methamphetamine on DAT uptake. Furthermore, PG01037 did not attenuate methamphetamine-induced decreases in dopamine and 5HT content. Taken together, the present study demonstrates that dopamine D3 receptors mediate, in part, the long-term deficits in DAT function caused by methamphetamine, and that this effect likely involves an attenuation of methamphetamine-induced hyperthermia.

KEYWORDS:

D(3) antagonist; Dopamine D(3) receptors; Dopamine transporter; Methamphetamine; PG01037; Serotonin transporter

PMID:
24685638
PMCID:
PMC4060957
DOI:
10.1016/j.ejphar.2014.03.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center